A randomised, open label comparative study of hydroxychloroquine with betamethasone oral mini pulse in the management of patients with alopecia areata
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20210189Keywords:
Betamethasone oral mini pulse, Hydroxychloroquine, Alopecia areataAbstract
Background: Alopecia areata is an autoimmune disorder causing patchy hair loss on scalp and other parts of the body and leading to poor self-esteem and anxiety in patients. Treatment with topical or systemic drugs like steroids or other immunosuppressants is associated with adverse effects. Hydroxychloroquine is an antimalarial drug, with T cell modulating function. This study was undertaken to assess the safety, efficacy and tolerability of Hydroxychloroquine in Alopecia areata compared to betamethasone oral mini pulse (OMP) therapy.
Methods: 60 patients with alopecia areata were randomized into two groups of 30 each. Control group received tab. betamethasone 5 mg/day on two consecutive days of week for 12 weeks and Study group received tab. hydroxychloroquine 200 mg/day for 12 weeks. They were followed-up for further 12 weeks. Scale of alopecia tool, dermatology life quality index and global assessment at baseline, 12 weeks and 24 weeks were used to assess the outcome.
Results: 94 patients were screened and 60 patients were included. All patients completed the study. At the end of 12 weeks, there was a statistically significant reduction in SALT and DLQI scores in both control and study groups. But at the end of 24 weeks, the study group showed an increase in the scores. Relapses were more in the study group. No significant difference in the incidence of adverse events was noted between the two groups.
Conclusions: Hydroxychloroquine 200 mg/day is less efficacious in the management of alopecia areata in comparison to betamethasone oral mini pulse therapy.
References
Seetharam KA. Alopecia areata: An update. Indian J Dermatol. 2013;79:563-75.
Cunliffe WJ, Hall R, Stevenson CJ, Weightman D. Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol. 1969;81:877-81.
Bolognia JL, Jorizzo JL, Schaffer JV, Callen JP, Cerroni L, Heymann WR. Dermatology, Third Edition, Northwestern university, Northwestern Scholars. 2012;1:1100.
Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: Frequency and clinical presentation. J Eur Acad Dermatol Venereol. 2009;23:240-1.
Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol (Stockh). 1984;64:26-30.
Dubois M, Baumstarck-Barrau K, Gaudy-Marqueste C, Richard MA, Loundou A, Auquier P et al. Quality of life in alopecia areata: A study of 60 Cases. J Invest Dermatol. 2010;130:2830-3.
Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res. 1980;267:109-14.
Mittal R, Sudha R, Murugan S, Adikrishnan , Shobana S, Anandan S. Pulse Therapy in Dermatology. Sri Ramachandra J Med. 2007;1(2):2007.
Adams EM, Yocum DE, Bell CL. Hydroxychloroquine in the treatment of rheumatoid arthritis. Am j med. 1983;75(2):321-6.
Stephan F, Habre M, Tomb R. Successful treatment of alopecia totalis with hydroxychloroquine: Report of 2 cases. JAAD. 2013;68(6):1048-9.
Urmila B, Sushil P. Scoring systems in dermatology. Indian J Dermatol Venereol Leprol. 2006;72(4):315-21.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6.
Hordinsky M, Kalish R. Plaquenil for Alopecia Totalis. Clinicaltrials.gov. 2009.
Duri Yu, Silverberg N, Stein SL. Alopecia areata and Hydroxychloroquine- A review of 8 cases. Pediatrics Dermatol. 2018;35(3):361-5.
Khaitan BK, Mittal R, Verma KK. Extensive alopecia areata treated with betamethasone oral mini-pulse therapy: An open uncontrolled study. Indian J Dermatol Venereol Leprol. 2004;70:350-3.
